PBTC-039 – Summary for Patients and Families Title: PBTC-039, Phase II study of Peginterferon alfa-2b (PEGIntron) for pediatric patients with unresectable or recurrent craniopharyngioma This is a brief summary of a cli - Peginterferon alfa-2b - Document - PDFSEARCH.IO

First Page	Meta Content
	PBTC-039 – Summary for Patients and Families Title: PBTC-039, Phase II study of Peginterferon alfa-2b (PEGIntron) for pediatric patients with unresectable or recurrent craniopharyngioma This is a brief summary of a cli Add to Reading List Document Date: 2013-12-23 10:31:23 Open Document File Size: 139,98 KB Share Result on Facebook Country United States / / / Facility National Cancer Institute / MD Children’s Hospital of Pittsburgh Telephone / / MedicalCondition fever / abdominal pain / tumor / vomiting / tumors / headache / muscle aches / chills / tiredness / craniopharyngioma / brain tumors / very large tumors / / MedicalTreatment radiation therapy / surgery / / Organization National Cancer Institute / Hospital of Pittsburgh Telephone / FDA / Cancer Information Service / PBTC / / Person Regina Jakacki / / / Product acetaminophen / PEGIntron / Peginterferon / / Technology radiation / MRI / / URL www.cancer.gov/clinicaltrials / www.cancer.gov / www.cancernet.org / / SocialTag Radiation therapy Radioactivity Radiobiology Methadone Craniopharyngioma Breast cancer treatment Atypical teratoid rhabdoid tumor Medicine Brain tumor Radiation oncology

PBTC-039 – Summary for Patients and Families Title: PBTC-039, Phase II study of Peginterferon alfa-2b (PEGIntron) for pediatric patients with unresectable or recurrent craniopharyngioma This is a brief summary of a cliAdd to Reading List